MX2020013895A - Agentes inhibidores de ask1. - Google Patents
Agentes inhibidores de ask1.Info
- Publication number
- MX2020013895A MX2020013895A MX2020013895A MX2020013895A MX2020013895A MX 2020013895 A MX2020013895 A MX 2020013895A MX 2020013895 A MX2020013895 A MX 2020013895A MX 2020013895 A MX2020013895 A MX 2020013895A MX 2020013895 A MX2020013895 A MX 2020013895A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- inhibiting agents
- ask1
- compounds
- ask1 inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan compuestos de fórmula (I): (ver fórmula I) , que incluyen compuestos de las Fórmulas (II), (III) y (IV), donde X, R1, R2, R3 y n son tal como se definen en la presente, y sales farmacéuticamente aceptables de estos, y métodos para su uso y producción; estos compuestos pueden ser útiles, por ejemplo, en el tratamiento de trastornos que responden a la inhibición de la cinasa reguladora de las señales de apoptosis 1 (ASK1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690674P | 2018-06-27 | 2018-06-27 | |
| PCT/US2019/039156 WO2020006031A1 (en) | 2018-06-27 | 2019-06-26 | Ask1 inhibiting agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013895A true MX2020013895A (es) | 2021-07-21 |
Family
ID=67254023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013895A MX2020013895A (es) | 2018-06-27 | 2019-06-26 | Agentes inhibidores de ask1. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11814362B2 (es) |
| EP (1) | EP3814333A1 (es) |
| JP (1) | JP2021528456A (es) |
| KR (1) | KR20210024532A (es) |
| CN (1) | CN112638896A (es) |
| AR (1) | AR115636A1 (es) |
| AU (1) | AU2019291806A1 (es) |
| BR (1) | BR112020026423A2 (es) |
| CA (1) | CA3104662A1 (es) |
| CL (1) | CL2020003375A1 (es) |
| CO (1) | CO2021000782A2 (es) |
| CR (1) | CR20210049A (es) |
| EA (1) | EA202190034A1 (es) |
| IL (1) | IL279709A (es) |
| JO (1) | JOP20200318A1 (es) |
| MA (1) | MA53009A (es) |
| MX (1) | MX2020013895A (es) |
| PE (1) | PE20211379A1 (es) |
| SG (1) | SG11202012784SA (es) |
| TW (1) | TW202035389A (es) |
| UY (1) | UY38278A (es) |
| WO (1) | WO2020006031A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202012972YA (en) | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Substituted naphthyridinone compounds useful as t cell activators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| TWI598347B (zh) | 2009-07-13 | 2017-09-11 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| WO2015095059A1 (en) * | 2013-12-20 | 2015-06-25 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
-
2019
- 2019-06-26 JO JOP/2020/0318A patent/JOP20200318A1/ar unknown
- 2019-06-26 PE PE2020002138A patent/PE20211379A1/es unknown
- 2019-06-26 CA CA3104662A patent/CA3104662A1/en not_active Abandoned
- 2019-06-26 TW TW108122356A patent/TW202035389A/zh unknown
- 2019-06-26 MX MX2020013895A patent/MX2020013895A/es unknown
- 2019-06-26 US US17/253,269 patent/US11814362B2/en active Active
- 2019-06-26 JP JP2020572645A patent/JP2021528456A/ja active Pending
- 2019-06-26 UY UY0001038278A patent/UY38278A/es not_active Application Discontinuation
- 2019-06-26 CN CN201980042586.9A patent/CN112638896A/zh active Pending
- 2019-06-26 AU AU2019291806A patent/AU2019291806A1/en not_active Abandoned
- 2019-06-26 SG SG11202012784SA patent/SG11202012784SA/en unknown
- 2019-06-26 BR BR112020026423-7A patent/BR112020026423A2/pt not_active Application Discontinuation
- 2019-06-26 EA EA202190034A patent/EA202190034A1/ru unknown
- 2019-06-26 KR KR1020217000614A patent/KR20210024532A/ko unknown
- 2019-06-26 AR ARP190101780A patent/AR115636A1/es unknown
- 2019-06-26 WO PCT/US2019/039156 patent/WO2020006031A1/en unknown
- 2019-06-26 MA MA053009A patent/MA53009A/fr unknown
- 2019-06-26 EP EP19739494.3A patent/EP3814333A1/en active Pending
- 2019-06-26 CR CR20210049A patent/CR20210049A/es unknown
-
2020
- 2020-12-23 CL CL2020003375A patent/CL2020003375A1/es unknown
- 2020-12-23 IL IL279709A patent/IL279709A/en unknown
-
2021
- 2021-01-25 CO CONC2021/0000782A patent/CO2021000782A2/es unknown
-
2023
- 2023-10-05 US US18/377,125 patent/US20240109867A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JOP20200318A1 (ar) | 2020-12-10 |
| SG11202012784SA (en) | 2021-01-28 |
| WO2020006031A1 (en) | 2020-01-02 |
| JP2021528456A (ja) | 2021-10-21 |
| WO2020006031A8 (en) | 2020-09-24 |
| MA53009A (fr) | 2021-05-05 |
| CA3104662A1 (en) | 2020-01-02 |
| US20210115020A1 (en) | 2021-04-22 |
| CR20210049A (es) | 2021-07-01 |
| AR115636A1 (es) | 2021-02-10 |
| IL279709A (en) | 2021-03-01 |
| PE20211379A1 (es) | 2021-07-27 |
| AU2019291806A1 (en) | 2021-01-07 |
| US11814362B2 (en) | 2023-11-14 |
| US20240109867A1 (en) | 2024-04-04 |
| CL2020003375A1 (es) | 2021-09-03 |
| UY38278A (es) | 2020-01-31 |
| CO2021000782A2 (es) | 2021-01-29 |
| EA202190034A1 (ru) | 2021-04-08 |
| EP3814333A1 (en) | 2021-05-05 |
| BR112020026423A2 (pt) | 2021-03-23 |
| CN112638896A (zh) | 2021-04-09 |
| KR20210024532A (ko) | 2021-03-05 |
| TW202035389A (zh) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001876A (es) | Derivados de rapamicina. | |
| TN2019000110A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2017010062A (es) | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. | |
| MX371167B (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta). | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| MX2020000404A (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
| MX2020009062A (es) | Piperidinil-3-(ariloxi)propanamidas y propanoatos. | |
| PH12019502334A1 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| MX2016016538A (es) | Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa. | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
| PH12015500063B1 (en) | Azaindole derivatives which act as pi3k inhibitors | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| SG10201806809QA (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| MX2017009824A (es) | Triazoles sustituidos y metodos relacionados a estos. | |
| CR20220160A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. | |
| MX2021002051A (es) | Imidazo[1,2-b]piridaziinas como inhibidores de trk. | |
| MX2021013135A (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2. | |
| MX2022007518A (es) | Derivados bencimidazol. | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones |